CJC-1295 vs Ipamorelin

This is the most-stacked GH-secretagogue pairing in research-peptide logs, and the reason is mechanism complementarity. CJC-1295 is a GHRH analog — it amplifies the body's own growth-hormone-releasing-hormone signal. Ipamorelin is a GHRP — a ghrelin-mimetic that triggers a GH pulse from the pituitary directly. Stacked, they push from both ends of the same pathway. Compared head-to-head, they are doing structurally different jobs even when the downstream effect (a GH pulse) looks similar in a log.

Half-life is the cadence-defining difference. CJC-1295 in its DAC form has a half-life measured in days, which lets it be administered as little as twice a week. Ipamorelin's half-life is on the order of two hours, which is why the standard protocol is two-to-three administrations a day. The same vial in the two molecules empties at completely different rates as a result — a 5 mg ipamorelin vial dosed three times daily empties in a couple of weeks, while a 5 mg CJC-1295 vial dosed twice weekly stretches across months.

Side-effect profile reads quite differently in logs. Ipamorelin is the most-selected member of the GHRP family precisely because it does not meaningfully move cortisol, prolactin, or appetite the way GHRP-2 and GHRP-6 do — that selectivity is the reason it gets paired with a GHRH analog rather than another GHRP. CJC-1295's profile in logs is dominated by the long half-life: very few injection-site events because the cadence is sparse, but any side-effect signal sticks around for days rather than hours.

For the stacked log, the recommended (sorry, common) workflow is parallel timelines rather than a merged single timeline. Ipamorelin gets its own field with three entries a day; CJC-1295 gets its own field with two entries a week. The mg-to-units calculator handles both molecules once their vial concentrations are set, and the vial-duration calculator linked below shows the very different rates at which each vial empties at typical protocol cadences.

For the CJC-1295 vs Ipamorelin decision specifically, the calendar shape is what most readers underweight. CJC-1295's example vial is 2 mg drawn against 0.1 mg per dose at 7 doses per week. Ipamorelin's example vial is 2 mg drawn against 0.2 mg per dose at 7 doses per week. Those four numbers feed every column in the table above; change any one and the cjc 1295 vs ipamorelin comparison shifts with it.

Concentration in this pair: CJC-1295 sits at 1.00 mg/mL on the example reconstitution; Ipamorelin sits at 1.00 mg/mL on its example. That single ratio is what determines how many U-100 syringe units a given dose of either molecule actually draws, so it is the first thing to confirm before treating any "CJC-1295 vs Ipamorelin" unit number on the internet as authoritative.

Doses per vial in this matchup work out to roughly 20 for CJC-1295 and 10 for Ipamorelin at the example dose sizes, with vial-duration windows near 2.9 weeks and 1.4 weeks respectively. Refill cadence follows directly from those windows, which is why the cjc 1295 vs ipamorelin pair shows up in planning conversations more than in pure mechanism conversations.

When readers compare CJC-1295 against Ipamorelin, the CJC-1295-side mistakes that show up most in logs are: Applying a daily dosing frequency appropriate for the no-DAC variant to the long-acting DAC variant. Logging a co-administered dose of CJC-1295 (no-DAC) and ipamorelin as a single combined entry, which desynchronizes per-vial inventory tracking. Failing to explicitly document whether the 'with DAC' or 'no-DAC' version was used, rendering the log data ambiguous and difficult to interpret later. Confusing the terminology and assuming 'Mod GRF 1-29' is a completely different compound rather than the specific name for CJC-1295 without DAC. Each of these gets amplified when a reader is also actively comparing against Ipamorelin, because muscle memory from one molecule's unit math leaks into the other.

CJC-1295 question worth answering up front — What is the functional difference between CJC-1295 with DAC and without DAC? The primary difference is the half-life and resulting dosing schedule. The DAC (Drug Affinity Complex) allows the peptide to bind to albumin in the blood, extending its half-life to about 6-8 days and enabling weekly or twice-weekly administration. The no-DAC version has a half-life of only about 30 minutes, requiring daily or multiple daily administrations to be studied.

CJC-1295 question worth answering up front — Why is CJC-1295 without DAC frequently paired with ipamorelin in research? This combination creates a synergistic effect by stimulating the pituitary gland through two separate pathways. CJC-1295 without DAC is a GHRH analog that stimulates the GHRH receptor, while ipamorelin is a ghrelin mimetic that stimulates the ghrelin receptor (GHSR). Activating both receptors at once results in a much larger release of growth hormone than stimulating either one alone.

On the Ipamorelin side of the CJC-1295 vs Ipamorelin decision, the recurring mistakes are: Administering doses at inconsistent times of day, which compromises the ability to observe long-term trends related to its selective action. Logging a combination like Ipamorelin/CJC-1295 as a single dose entry, which inevitably causes errors in vial inventory management for each separate peptide. Misinterpreting the designed absence of an appetite spike as a sign that the peptide is inactive or low in potency. Scheduling administration shortly after a meal containing carbohydrates or fats, thereby blunting the potential GH pulse via insulin release. These are not generic dosing slips — they are the ones that compound when Ipamorelin is being logged in parallel with CJC-1295.

Ipamorelin question worth answering up front — What is the primary distinction between Ipamorelin and GHRP-6? The defining distinction is selectivity. Ipamorelin was developed specifically to stimulate growth hormone release with high potency while avoiding the significant increases in appetite, cortisol, and prolactin that are characteristic of older secretagogues like GHRP-6. This targeted action results from its refined molecular structure and specific binding profile.

Ipamorelin question worth answering up front — Why is Ipamorelin often studied in combination with CJC-1295 without DAC? This combination is studied because it targets two separate pituitary receptors to synergistically amplify GH release. Ipamorelin acts on the ghrelin receptor while CJC-1295 (no DAC) acts on the GHRH receptor. Activating both pathways at once generates a more robust GH pulse than using either peptide alone, while still honoring the body's natural pulsatile rhythm.